Ligation of the CD2 co-stimulatory receptor on human T lymphocytes induces tyrosine phosphorylation and activation of the Tec-family tyrosine kinase, ITK. To examine whether any of several proline-rich (PR) stretches of the CD2 cytoplasmic tail are necessary for ITK activation we introduced wild-type and mutated versions of rat CD2, each missing at least one PR stretch of the tail, into human Jurkat T leukemia cells. The influence of cytoplasmic tail mutations was then studied following stimulation of transfectants with the rat CD2 mAb pair, OX54/OX55. As predicted, wild-type rat CD2 was able to activate ITK in Jurkat cells. In addition, a truncation mutant, lacking the most membrane-distal PR stretch, PR6, was able to activate ITK. By contrast, all other studied truncation mutants, each of which is missing at least PR4-PR6, were unable to induce ITK activation. Of deletion mutants, deletion of the membrane-proximal PR stretches, PR1-PR3, did not impair rat CD2-mediated ITK activation. However, additional deletion of PR4 from a tail missing PR1 and PR2, deletion of PR2 and PR4, and deletion of PR4 alone from rat CD2 abrogated an ability to activate ITK. Thus, these results identify PR4 as an element of the CD2 tail that is required for activation of ITK. Furthermore, we show that, unlike wild-type rat CD2, PR4-deleted rat CD2 is unable to induce IL-2 secretion from Jurkat cells. This is consistent with the view that PR4-mediated activation of ITK is important for downstream signaling events induced by CD2 co-stimulation.
Introduction
The CD2 receptor is a 50 kDa type I transmembrane glycoprotein of the Ig superfamily expressed on the surface of thymocytes, T cells and NK cells (1, 2) . It has long been recognized that ligation of human CD2 with pairs of CD2 mAb stimulates cytokine production, proliferation and cytotoxicity in these cell types. Furthermore, CD2 mAb and the natural ligand of human CD2, CD58, can synergize with TCR generated signals to induce T cell activation. This has led to the concept of CD2 as a T cell co-stimulatory receptor (3) (4) (5) (6) (7) (8) . More recently it has been shown that the CD2-CD58 interaction is uniquely required for the reversal of T cell anergy resulting from blockade of CD28 co-stimulatory signals during an earlier antigenic challenge (9) . In addition, CD2 signaling can protect human T cells from Fas-mediated apoptosis induced through CD3 engagement (10) . However, CD2 might not have Correspondence to: P. D. King, Division of Rheumatology, Hospital for Special Surgery, Cornell University Medical Center, New York, NY 10021, USA Transmitting editor: T. Sasazuki Received 29 January 1998, accepted 31 March 1998 an exclusive positive role in human T cell activation. Thus, some CD2 mAb can themselves mediate T cell apoptosis through stimulation of a novel death pathway (11) . Studies of whole animals provide further testament to an important role for CD2 in T cell function. Although early reports of CD2 knockout mice documented an immunologically normal phenotype (12, 13) , subsequent studies have revealed subtle defects in both thymocyte development and peripheral T cell responsiveness. For example, CD2 knockout mice expressing TCR transgenes exhibit enhanced thymocyte positive selection and impaired T cell proliferation and cytokine production. Similarly, CD2/CD5 double-knockout mice show enhanced positive selection of thymocytes (14) . These findings suggest that CD2 functions as a negative signaling molecule during thymocyte positive selection and as a positive signaling molecule in physiologic peripheral T cell immune responses. In accordance with a negative signaling role during positive selection, expression of a human CD2 transgene in mouse thymocytes results in increased apoptosis of thymocytes at the CD4/CD8 double-positive stage (15) . Also, the function of CD2 as a positive signaling molecule in the periphery is consistent with the finding that administration of non-depleting CD2 antibodies to mice profoundly inhibits the ability of T cells to respond to nominal antigens (16) .
It is appreciated that CD2-mediated cytokine production in T and NK cells requires co-expression of the CD3ζ chain and the transmembrane tyrosine phosphatase, CD45 (17) (18) (19) . Earlier signaling events induced by CD2, however, appear independent of CD3ζ chain expression. One early signaling event that does not require ζ chain expression is activation of the Src-family protein tyrosine kinase (PTK), LCK (20) . LCK has been shown to bind directly to CD2 via SH3 domain recognition of defined proline-rich (PR) stretches present in the CD2 cytoplasmic tail (21, 22) . Recently, we have demonstrated that another PTK, the Tec-family kinase, ITK (also known as EMT or TSK), becomes activated during CD2 signaling. Activation of ITK is independent of CD3ζ but requires coexpression of functional LCK (23) . ITK activation has also been observed following ligation of the TCR and CD28 (24) (25) (26) (27) . Moreover, in the case of CD28 signaling, a membrane proximal PR stretch of the CD28 cytoplasmic tail has been shown to serve as a docking site for ITK and to mediate ITK activation (28) . In light of these observations, in the current studies, we asked whether PR stretches of the CD2 tail are necessary for CD2-mediated activation of ITK. To address this question we studied the ability of cytoplasmic tail mutants of rat CD2 to activate ITK in human Jurkat T leukemia cells. Our results indicate that ITK activation is controlled by a single CD2 cytoplasmic tail PR stretch, PR4. We additionally demonstrate that deletion of PR4 from rat CD2 abrogates an ability of the receptor to induce IL-2 from Jurkat cells.
Methods

Rat CD2 cDNA constructs
Methods used for the generation of wild-type, truncation mutant (CY40, CY78, CY85 and CY105) and deletion mutant (CY49.69) rat CD2 cDNAs have been described (22) . In addition, for the current studies we produced PR3, PR4, PR2/4 and CY49.69/PR4 deletion mutants, again by overlap PCR (29) . Respectively, these cDNAs encode for rat CD2 proteins that are deleted of residues 75-85, 90-97, 60-68 and 90-97, and 50-68 and 90-97 inclusive, of the cytoplasmic tail sequence (22, 30) . For expression in Jurkat cells all rat CD2 cDNAs were subcloned into either the XhoI site of BSRαEN (31) or the EcoRI site of pcDNA3 (Invitrogen, San Diego, CA) mammalian cell expression vectors.
Jurkat transfection
The Jurkat clone E6.1 (ATCC, Rockville, MD) was maintained in RPMI 1640 supplemented with 5% FCS, 2 mM L-glutamine and antibiotics (complete medium). Jurkat cells were transfected by electroporation using a BioRad Gene Pulser (BioRad, Richmond, CA). For this purpose, exponentially growing Jurkat were washed 4 times in PBS and for each transfection 2ϫ10 7 Jurkat cells were pre-incubated with 20 µg of DNA in electroporation cuvettes for 15 min on ice. Settings for electroporation were 250 V and 960 µF. Following electroporation, cells were cultured for 48 h in complete medium. G418 (Life Technologies, Grand Island, NY) was then added to cells (1 mg/ml final concentration) and cells were seeded into 96-well culture plates at 2ϫ10 4 cells/well. After 3-4 weeks of culture G418 resistant clones were analyzed for rat CD2 and endogenous human CD2 expression by flow cytometry. Primary mouse mAb used in flow cytometry experiments were OX34 (anti-rat CD2/IgG2a) and 9.6 (anti-human CD2/IgG2a). The secondary detection reagent was goat anti-mouse Ig (GAM)-FITC (Becton Dickinson, Mountain View, CA). Clones that expressed comparably high cell surface levels of rat and human CD2 were selected for further study.
ITK tyrosine phosphorylation and kinase activity Jurkat transfectants were rested by overnight serum starvation followed by 1 h incubation in PBS at room temperature (23, 27) . Aliquots of cells (50ϫ10 6 /data point) were then pelleted and incubated on ice in 300 µl of PBS with or without 10 µg/ml each of murine mAb OX54 (anti-rat CD2/IgG1) plus OX55 (anti-rat CD2/IgG1) or 9.6 (anti-human CD2/IgG2a) plus 9-1 (anti-human CD2R/IgG3). After 1 h cells were washed once in ice-cold PBS, resuspended in 300 µl of room temperature PBS containing 40 µg/ml of GAM (Sigma, St Louis, MO) and transferred to a 37°C water bath for 3 min. Cells were then lysed by the addition of an equal volume of 2ϫNP-40 lysis buffer (1ϫNP-40 ϭ 150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1 mM Na 3 VO 4 , 1 mM PMSF) and incubation on ice for 15 min. Post-nuclear lysates were pre-cleared by rotation with 200 µl of packed Sephadex G-50 beads (Sigma) for 2 h. Subsequently, ITK was precipitated from lysates by rotation for 1 h with 20 µl of Protein A-agarose beads (Life Technologies) that had been pre-coated with a rabbit polyclonal anti-ITK antiserum.
To determine ITK phosphotyrosine content beads were washed 5 times in 1ϫNP-40 lysis buffer and boiled for 5 min in reducing SDS sample buffer. Eluted proteins were then size-fractionated on 10% polyacrylamide gels and transferred to PVDF membranes (Dupont NEN, Boston, MA). Membranes were blocked with 10% FCS/Tris-buffered saline with 0.1% Tween 20 (TTBS) and then probed with a 1:4000 dilution of an anti-phosphotyrosine mAb, RC20, coupled to horseradish peroxidase (RC20-HRP; Transduction Laboratories, Lexington, KY) contained in the same solution. Membranes were washed extensively in TTBS before detection of bound antibody by ECL using Renaissance Western blot reagent (Dupont NEN).
To check for equal loading of ITK blots were stripped and re-probed with a 1:1000 dilution of ITK anti-serum in 10% milk/TTBS. Blots were then washed in TTBS and probed with a 1:1000 dilution of Protein A-HRP (Zymed, San Francisco, CA), again in 10% milk/TTBS. After a final set of washes in TTBS blots were developed by ECL.
To assess ITK tyrosine kinase activity beads were washed 5 times in 1ϫNP-40 lysis buffer and resuspended in 150 µl of 25 mM HEPES, pH 7.5, 7.5 mM MgCl 2 , 1.5 mM MnCl 2 , 1 mM Na 3 VO 4 with 20 µCi [γ-32 P]ATP (Dupont NEN) and 10 µg of Src peptide (Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-AlaArg-Gly; Sigma). After 15 min at 30°C beads were pelleted and 3ϫ25 µl aliquots of supernatants were spotted onto P81 phosphocellulose paper (Whatman, Maidstone, UK). Spots were air dried, washed 6 times with 1% phosphoric acid and Src peptide phosphorylation was determined by scintillation counting.
To check that equal quantities of ITK were analyzed in Src peptide phosphorylation assays and to determine ITK autokinase activity, pelleted beads were boiled in reducing SDS sample buffer and eluted proteins were run on 10% polyacrylamide gels and transferred to PVDF membranes. ITK was detected by probing membranes with an ITK antiserum followed by Protein A-HRP as described above. Autophosphorylation of ITK was determined by auto-radiography.
Jurkat IL-2 induction
Exponentially growing Jurkat transfectants were washed once in PBS and plated into 96-well plates at 1ϫ10 5 cells/well. Cells were stimulated with combinations of PMA (0.1 ng/ml; Sigma) plus ionomycin (1 µM; Sigma), OX54 plus OX55 mAb and 9-1 plus 9.6 mAb. Culture medium was complete RPMI and total well volume was 200 µl. After 24 h supernatants were assayed for IL-2 content using IL-2 ELISA kits (Genzyme, Cambridge, MA).
Results
Expression of rat CD2 cytoplasmic tail mutants in Jurkat cells
We have demonstrated previously that perturbation of the CD2 antigen on Jurkat T leukemia cells with the use of pairwise combinations of CD2 mAb results in the activation of ITK (23) . We were interested to determine which regions of the CD2 cytoplasmic tail and, in particular, whether PR stretches of the tail are necessary for this activation. To examine this we stably transfected Jurkat cells with wild-type and mutated versions of rat CD2. Rat CD2 was chosen since an anti-rat CD2 mAb pair is available, i.e. OX54 plus OX55, which has been shown to activate rat T cells (32) . Hence, with the use of OX54/OX55 it should be possible to study the influence of rat CD2 mutations in Jurkat in the absence of endogenous human CD2 signaling. Mutants of rat CD2 studied included truncation mutants (CY40, CY78, CY85 and CY105) and deletion mutants (CY49.69, PR3, PR4, PR2/4 and CY49.69/PR4) of the cytoplasmic tail (Fig. 1) . Each of these mutants are missing one or more of the six PR stretches, designated PR1-PR6, present in the rat CD2 tail. Following transfection of Jurkat, cells were cloned and analyzed for expression of rat CD2 versus endogenous human CD2 by FACS. Clones that expressed equivalent high levels of rat and human CD2 were used in further experiments (Fig. 2) .
ITK tyrosine phosphorylation
We first examined the ability of rat CD2 variants to induce tyrosine phosphorylation of ITK. For these experiments different transfectants were stimulated or not with OX54 plus OX55 for 3 min at 37°C. In addition, transfectants were also stimulated with the anti-human CD2 mAb pair, 9-1 plus 9.6, as an internal control. Following mAb stimulation, cells were lysed, ITK was precipitated and phosphotyrosine content of ITK was analyzed by Western blotting. Results obtained with all transfectants are shown in Fig. 3 . As expected, wild-type rat CD2 was able to induce tyrosine phosphorylation of ITK. Furthermore, this tyrosine phosphorylation was comparable to that induced by human CD2 ligation on the same cell. Similarly, the CY105 truncation mutant, which lacks PR6 of the rat CD2 tail, induced tyrosine phosphorylation of ITK to the same extent as endogenous human CD2 on that clone. This result was also expected since PR6 is not present in the human CD2 cytoplasmic tail. By contrast, the other truncation mutants, CY40, CY78 and CY85, which lack PR stretches PR1-PR6, PR3-PR6 and PR4-PR6 respectively, all failed to induce any tyrosine phosphorylation of ITK. Collectively, therefore, these results suggest that PR1, PR2, PR3 and PR6 are not involved, and that either or both of PR4 and PR5 are necessary for rat CD2-mediated ITK tyrosine phosphorylation.
Consolidating the lack of a role for PR1-PR3 of the rat CD2 tail, the CY49.69 deletion mutant, which is missing PR1 and PR2, and the PR3 deletion mutant, which is missing PR3 only, were both able to induce as much tyrosine phosphorylation of ITK as endogenous human CD2. However, the CY49.69/ PR4 deletion mutant, missing PR1, PR2 and PR4, the PR2/4 deletion mutant, missing PR2 and PR4, and the PR4 deletion mutant, missing PR4 only, all failed to induce ITK tyrosine phosphorylation. These last results, therefore, illustrate a 
ITK tyrosine kinase activity
In addition to ITK tyrosine phosphorylation we also examined the ability of rat CD2 mutants to induce increases in the tyrosine kinase activity of ITK. For this purpose, different rat CD2 transfectants were again stimulated or not with rat or human CD2 mAb pairs for 3 min. ITK was then precipitated from cells and the transphosphorylating ability of ITK was assessed in in vitro kinase assays using a Src peptide as a substrate. Figure 4 depicts the results of a typical experiment Fig. 3 . Induction of ITK tyrosine phosphorylation by rat CD2 mutants. The indicated rat CD2 Jurkat transfectants were stimulated with human CD2 mAb (9-1/9.6) plus GAM (Hu CD2XL) or rat CD2 mAb (OX54/OX55) plus GAM (Rat CD2XL) for 3 min at 37°C. Control (Mock) stimulated cells were identically treated except that primary mAb were not used. Cells were lysed, ITK was precipitated from lysates and phosphotyrosine content of ITK was determined by Western blotting using an anti-phosphotyrosine mAb (pTyr). Blots were stripped and re-probed with an ITK antiserum to determine equal loading of ITK (ITK). As shown, equivalent quantities of ITK were analyzed in each experiment. All bands shown are~70 kDa.
which examines the wild-type and CY78 transfectant clones. As shown (Fig. 4, upper left) , wild-type rat CD2 induced an increase in ITK transphosphorylating activity which peaked at 3 min and returned to almost resting levels by 10 min poststimulation. The magnitude and time course of this increase was similar to that seen following endogenous human CD2 stimulation. Likewise, wild-type rat CD2 induced an increase in ITK autokinase activity comparable to that induced by human CD2 (Fig. 4, upper right) . In contrast to this, the CY78 truncation mutant failed to induce any increase in ITK transphosphorylating activity or autokinase activity (Fig. 4,  bottom) , unlike endogenous human CD2 on that clone. Similar experiments were performed with other rat CD2 transfectants. The results of one representative experiment of several performed upon each clone are summarized in Figure 5 which shows CD2-induced fold increases in ITK transphosphorylating activity at the 3 min time point. As shown, the results obtained with this panel of mutants paralleled results obtained in phosphotyrosine blotting experiments. Thus, in addition to wild-type rat CD2, the CY49.69 rat CD2 deletion mutant also induced activation of ITK kinase activity to a similar extent as endogenous human CD2. However, none of the remaining studied rat CD2 mutants, which included CY40, CY78, CY85, CY49.69/PR4, PR2/4 and PR4, induced appreciable activation of ITK kinase activity when compared to endogenous human Fig. 4 . CD2 induced increases in ITK tyrosine kinase activity in wildtype and CY78 rat CD2 transfectants. Wild-type and CY78 rat CD2 Jurkat transfectants were mock stimulated or stimulated with human or rat CD2 mAb for 3 or 10 min as indicated in the legend to Fig. 3 . Cells were lysed, ITK was precipitated from lysates and kinase activity was assessed by an ability to transfer 32 P to both a Src peptide substrate (transphosphorylation, left panels) and itself (autophosphorylation, right panels). Equivalent precipitation of ITK was verified by Western blotting (not shown).
CD2 stimulation. These results confirm that PR4 of the rat CD2 tail plays an important role in the activation of ITK.
IL-2 induction by the rat CD2 PR4 deletion mutant
The definition of PR4 as a region of the CD2 cytoplasmic tail necessary for the activation of ITK prompted us to examine whether the PR4 deletion mutant could induce IL-2 secretion from Jurkat cells. We examined IL-2 secretion using suboptimal concentrations of phorbol myristate acetate (PMA; 0.1 ng/ml) and ionomycin (1 µM) as a co-stimulus. The results of two different experiments are presented in Table 1 . In experiment 1 we used the same wild-type and PR4 rat CD2 transfectant clones as before (Fig. 2) . In experiment 2 we used different wild-type and PR4 transfectant clones that express similarly high levels of human and rat CD2 (not shown). As shown, in these experiments transfected wildtype rat CD2 was able to induce 70-75% the amount of IL-2 from Jurkat cells as endogenous human CD2. In contrast, the PR4 deletion mutant induced Ͻ10% the amount of IL-2 stimulated by human CD2. These results are consistent with the notion that activation of ITK by CD2 is necessary for CD2-mediated induction of IL-2 secretion.
Discussion
Herein we have undertaken a mutational analysis of the CD2 cytoplasmic tail in order to determine which of several PR stretches of the tail play a role in CD2-mediated activation of the Tec-family PTK, ITK. With the use of truncation mutants of rat CD2 we were able to define a region of the CD2 cytoplasmic tail, between residues 85 and 106, that is necessary for ITK activation. This region of the tail contains two PR stretches, PR4 and PR5. Simple deletion of PR4 from the CD2 tail abrogated an ability of CD2 to activate ITK. Barring the possibility of gross cytoplasmic tail conformational changes induced by the PR4 deletion this finding strongly suggests that PR4 of the CD2 tail plays a role in the activation of ITK. Theoretically, PR5 could also contribute to ITK activation. However, since the PR4 deletion mutant is inactive then PR5 is insufficient to mediate ITK activation.
Previous studies, which examined the mechanism of binding of the Src-family PTK, LCK, to the rat CD2 cytoplasmic tail, showed that this interaction was mediated by LCK SH3 domain recognition of PR2 and PR4 (22) . Depletion of either PR2 or PR4 from the cytoplasmic tail did not prevent LCK binding, presumably because these receptors contain one remaining LCK binding site. From these observations, and in the context that functional LCK is required for CD2-mediated activation of ITK, it seems unlikely that the role of PR4 in ITK activation can be explained in terms of a requirement of this PR stretch in LCK activation. Thus, receptors such as the CY85 truncation mutant and the PR4 deletion mutant would still be expected to activate LCK via PR2. Certainly, in reverse, PR4, in the absence of PR2, is sufficient for CD2-mediated LCK activation. This can be inferred from the fact that the CY49.69 receptor is able to fully activate ITK (Figs 3 and 5) .
One obvious way in which PR4 could play a distinct role in ITK activation is through function as a docking site for the Rat  CD2XL  CD2XL  CD2XL  CD2XL   1  700  500  300  10  2  400  300  950  80 Wild-type and PR4 rat CD2 Jurkat transfectants were stimulated with human CD2 mAb (9-1/9.6) or rat CD2 mAb (OX54/OX55) in the presence of PMA (0.1 ng/ml) and ionomycin (1 µM) for 24 h. IL-2 concentrations in supernatants were determined by ELISA. Assays were performed in duplicate and data are presented as mean IL-2 secretion (pg/ml) for each type of stimulation. SE were Ͻ5% of the mean. Negligible quantities of IL-2 (Ͻ20 pg/ml) were induced from transfectants stimulated with CD2 mAb pairs alone or PMA and ionomycin alone. Different wild-type and PR4 rat CD2 transfectant clones were used in Experiments 1 and 2.
ITK SH3 domain. As such, PR4 could serve to recruit ITK to the CD2 signaling complex where it might become transphosphorylated and activated by LCK (32, 33) . Indeed, it has been reported that ITK binds to a membrane-proximal PR stretch present in the cytoplasmic tail of another co-stimulatory receptor, CD28 (28) . Despite this, we have thus far been unable to detect any physical association between CD2 and ITK in co-immunoprecipitation experiments. Furthermore, we have been unable to detect any binding between ITK and synthetic peptides representing each of the PR stretches of the rat CD2 tail, including PR4 (22) . It should also be taken into account that PR4 of the CD2 tail (and all other PR stretches of the CD2 tail) does not conform to the consensus recognition motif defined for the ITK SH3 domain (34, 35) . It remains possible, however, that PR4 does bind ITK with weak affinity that is below the detection limit of our assays.
Another way in which PR4 may be involved in ITK activation is by binding and activation of some other SH3 domaincontaining signaling intermediate that together with LCK is upstream of ITK. One candidate is the lipid/serine kinase, phosphatidylinositol 3-kinase (PI3K). PI3K has been shown to bind to CD2 and to become activated following CD2 triggering (36, 37) . Phosphorylated lipid products of PI3K, through interaction with the ITK pleckstrin homology domain, could serve to localize ITK to the inner leaflet of the cell membrane. In turn, this could lead to activation of ITK by juxtaposition to LCK (38) (39) (40) . A still further route by which PR4 could link to ITK is through stimulation of hetero-trimeric guanine-nucleotide-binding proteins (G-proteins) which have been shown to bind to and activate Tec-family kinases (41, 42) .
Whether ITK is required for receptor-mediated T cell activation has been addressed recently. In ITK knockout mice, TCR-mediated signaling is impaired whereas CD28-mediated signaling is not (43, 44) . By contrast, in Jurkat cells, a dominant-negative version of ITK blocks both TCR and CD28 signaling suggesting a required role for ITK in both of these pathways in human T cells (45) . CD2 signaling in ITK knockout mice has not yet been studied. However, the same dominantnegative version of ITK that blocks TCR and CD28 signaling in Jurkat also blocks CD2 signaling in this cell line (45) . This suggests that ITK activation is also necessary for human CD2-induced responses. In the current studies, we show that the PR4 rat CD2 deletion mutant, which is unable to activate ITK, is also unable to induce IL-2 secretion in Jurkat cells. As well as defining an additional region of the CD2 cytoplasmic tail involved in IL-2 induction (46) (47) (48) , this finding lends weight to the notion that ITK activation contributes to CD2-induced downstream signaling events.
The exact function of ITK during CD2 signaling is not clear at present. However, by analogy to BTK, the B cell homologue of ITK, one possibility is that ITK synergizes with SYK-family PTK to induce phospholipase C-γ activation and intracellular calcium mobilization (49) . Consistent with this possibility is the recent finding that perturbation of CD2 on NK cells also induces the activation of SYK itself (50) . Other targets of ITK remain to be identified. This will permit a greater understanding of how CD2 functions in thymocyte selection and activation of peripheral T and NK cells.
